- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.08. | H.C. Wainwright bestätigt Kaufempfehlung für Tscan Therapeutics nach positiven Studiendaten | 1 | Investing.com Deutsch | ||
| 13.08. | H.C. Wainwright reiterates Tscan Therapeutics stock rating at buy | 1 | Investing.com | ||
| 12.08. | TScan Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.08. | TScan Therapeutics GAAP EPS of -$0.23 misses by $0.02, revenue of $1.05M misses by $0.83M | 1 | Seeking Alpha | ||
| 12.08. | TScan Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.08. | TScan Therapeutics, Inc.: TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update | 425 | GlobeNewswire (Europe) | First patient dosed in Phase 3 ALLOHA-2 study; topline readout expected mid-2028 Shared positive initial data from Cohort C of Phase 1 ALLOHA study, validating internal commercial-ready manufacturing... ► Artikel lesen | |
| TSCAN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 29.07. | TScan verabreicht erstem Patienten Dosis in Phase-3-Studie zu AML und MDS | 2 | Investing.com Deutsch | ||
| 30.06. | TScan Therapeutics auf der H.C. Wainwright Konferenz: Phase-III-Studie für TSC-101 gewinnt an Fahrt | 1 | Investing.com Deutsch | ||
| 22.06. | TScan Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 22.06. | TScan Therapeutics, Inc.: TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation | 436 | GlobeNewswire (Europe) | 11 of 14 patients dosed had complete donor chimerism within ~three weeks of receiving first infusion of TSC-101; an additional two had improving chimerism following TSC-101 TSC-101 continues to be... ► Artikel lesen | |
| 04.06. | Cellares and TScan to assess automated manufacturing of TSC-101 therapy | 1 | Pharmaceutical Technology | ||
| 03.06. | Cellares, TScan Partner to Automate Manufacture of TCR-T Candidate | 1 | Contract Pharma | ||
| 22.05. | TScan Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.05. | TScan Therapeutics GAAP EPS of -$0.22 misses by $0.01, revenue of $1M misses by $1.5M | 1 | Seeking Alpha | ||
| 06.05. | TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates | 1 | Zacks | ||
| 06.05. | TScan Therapeutics, Inc.: TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | 395 | GlobeNewswire (Europe) | Early data on patients treated in Cohort C of the ALLOHA Phase 1 heme trial expected in the second quarter of 2026 Initiation of Phase 3 study of TSC-101 (ALLOHA-2) planned for the second quarter... ► Artikel lesen | |
| 06.05. | TScan Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 06.05. | TScan Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 27.04. | TScan Therapeutics, Inc.: TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting | 4 | GlobeNewswire (USA) | ||
| 09.04. | H.C. Wainwright bestätigt Kaufempfehlung für Tscan-Aktie mit Kursziel 7 US-Dollar | 4 | Investing.com Deutsch |
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 88,30 | +0,11 % | BioNTech Aktie: Im Rausch der Moderna-Euphorie - Doch wie lange hält die Party an? | © Foto: von fernando zhiminaicela auf Pixabay (Symbolbild)Fast 30 Prozent in einer einzigen Woche. Das ist lange her, dass sowas bei BioNTech vorkam. Zuletzt wohl zu Pandemie-Zeiten ging es mal so zur... ► Artikel lesen | |
| MEDIGENE | 0,006 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 30.06.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 30.06.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 30.06.2026ISIN NameBE0003593044 COFINIMMOCA8765111064 TASEKO... ► Artikel lesen | |
| VALNEVA | 2,798 | +0,76 % | Katalysator voraus: Valneva (ISIN: FR0004056851) setzt auf Q3-Shigella-Daten | ||
| AMGEN | 371,90 | -0,35 % | Amgen: Tezspire Demonstrates Positive Phase 3 Results In Eosinophilic Esophagitis Across Both Co-primary And All Key Secondary Endpoints | Statistically Significant and Clinically Meaningful Disease and Symptom Improvements Compared to Placebo Maintained Through Week 52
Efficacy in a Third Epithelial-Driven... ► Artikel lesen | |
| BIOGEN | 187,62 | -0,51 % | Veeva Systems: Veeva Vault CRM Selected by Biogen | Unified commercial platform to help speed the delivery of medicines to patientsPLEASANTON, Calif., Aug. 25, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Biogen has... ► Artikel lesen | |
| BIOFRONTERA | 2,500 | +2,46 % | PTA-Adhoc: Biofrontera AG: Biofrontera AG beschließt Vorbereitung des Wechsels vom regulierten Markt (Prime Standard) in das Börsensegment Scale | DJ PTA-Adhoc: Biofrontera AG: Biofrontera AG beschließt Vorbereitung des Wechsels vom regulierten Markt (Prime Standard) in das Börsensegment Scale
Veröffentlichung von Insiderinformationen gemäß... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 682,40 | -0,41 % | Veeva Systems: Veeva Vault CRM Selected by Regeneron | Leading biopharma company selects agentic CRM for life sciences to generate Commercial EvidencePLEASANTON, Calif., Aug. 25, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced... ► Artikel lesen | |
| EDITAS MEDICINE | 2,750 | +0,73 % | Editas Medicine, Inc.: Editas Medicine Announces Second Quarter 2026 Results and Business Updates | EDIT-401 on track for CTN submission this month with data update in Q1 2027 Recently presented pre-clinical data demonstrating ~90% or greater mean reduction in multiple atherogenic lipoproteins,... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 1,125 | -0,88 % | Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026 | Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026
Halle (Saale) / Munich, Germany, August 18, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7)... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 18,240 | +1,33 % | Biotech-Player: Zelltherapie als Comeback-Story im Milliardenmarkt. Neue Ideen nach Corona von BioNTech, Qiagen und Biotech AG | ||
| IMMATICS | 8,260 | +1,29 % | Immatics Announces $150 Million Underwritten Offering | Houston, Texas and Tuebingen, Germany, August 25, 2026 - Immatics N.V. (NASDAQ: IMTX, "Immatics" or the "Company"), the global leader in precision targeting of PRAME with multiple clinical-stage programs... ► Artikel lesen | |
| LAKEFRONT BIOTHERAPEUTICS | 25,080 | +0,16 % | Lakefront Biotherapeutics: Lakefront Receives Transparency Notification from Bank of America | Mechelen, Belgium; August 24, 2026, 22.01 CET; regulated information - Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) received a transparency notification from Bank of America.
Pursuant... ► Artikel lesen | |
| TRAWS PHARMA | 0,590 | 0,00 % | Traws Pharma, Inc.: Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights | Advancing tivoxavir marboxil toward MHRA resubmission in Q3 2026 with a revised toxicology package, supporting initiation of the Phase 2a human influenza Challenge studyCompleted the April 2026 private... ► Artikel lesen | |
| VERASTEM | 6,280 | +0,71 % | Mizuho lowers Verastem stock price target on valuation to $13 | ||
| TRINITY BIOTECH | 9,700 | +0,31 % | Trinity Biotech expands PrePsia patent portfolio to nine patents |
TSCAN THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,753 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TSCAN THERAPEUTICS INC finden Sie auf Wallstreet Online.